The chairman of a House Energy and Commerce subcommittee criticized the FDA of "stonewalling, slow-rolling and plain incompetency" for failing to fully respond to his requests for information related to studies suggesting a link between antidepressant use by children and suicidal tendencies. A spokesperson for the FDA said it must adhere to laws restricting its ability to publicize corporate data. The subcommittee also heard from drug company representatives who said they hope to fix their credibility problems related to clinical trial information by releasing more information, but who also warned the information could be so voluminous and unwieldy it could be of little use to doctors and patients.

Related Summaries